

URGENT: DRUG RECALL

July 10, 2025

Bicillin® L-A Penicillin G Benzathine Injectable Suspension

Carton NDC	Syringe NDC	Lot Number	Expiration Date YYMMDD	Strength	Configuration/ Count
60793-701-10	60793-701-02	GL2954	270131	1,200,000 units/ 2 mL	10 (2 mL) syringes per carton, 24 cartons per shipping case
		HP6222	270131		
		HP6228	271031		
		HP6232	270930		
		HR9967	270531		
		HJ3235	260930		
		LT5190	270930		
60793-702-10	60793-702-04	GT2598	260930	2,400,000 units/ 4 mL	10 (4 mL) syringes per carton, 24 cartons per shipping case
		GT2599	260930		
		HR9969	270430		
		HK2909	270228		
		HR9984	270831		

Dear Customer:

King Pharmaceuticals LLC., a subsidiary of Pfizer, is voluntarily recalling the above referenced lots of **Bicillin® L-A (Penicillin G Benzathine Injectable Suspension)**. Pfizer is initiating this recall due to particulates identified during visual inspection. Pfizer has completed a Health Hazard Assessment which indicated that the potential risk to patients from use of the impacted product is medium.

To date, Pfizer has not received reports of any adverse events associated with this issue.

FEDERAL REGULATION 21 CFR 7.49 (d) RESPONSIBILITY OF RECIPIENT STATES: "CONSIGNEES THAT RECEIVE A RECALL COMMUNICATION SHOULD IMMEDIATELY CARRY OUT THE INSTRUCTIONS SET FORTH BY THE RECALLING FIRM ... "PFIZER RECOMMENDS THAT YOU RESPOND TO THIS RECALL EVEN IF YOU DO NOT HAVE THE RECALLED PRODUCT. TO RESPOND, COMPLETE THE REQUESTED INFORMATION ON THE ENCLOSED BUSINESS REPLY FORM (BRF) AND RETURN IT, AS DIRECTED, WITHIN FIVE (5) BUSINESS DAYS. If you have any questions about responding to this letter, please contact Sedgwick at 1-800-805-3093 (Mon.-Fri. 8 am-5 pm ET).



The recall of the above referenced lots of Bicillin® L-A (Penicillin G Benzathine Injectable Suspension) is being conducted to the **Hospital/Institution** level. Enclosed are product photos and labels for ease of identifying the impacted product.

Our records indicate that you received shipment of the affected product lots which was distributed from **December 11, 2023 through June 24, 2025**. Please check your stock immediately against the table above. If you have any of the affected lots in your inventory, please discontinue use, stop distribution and quarantine the product immediately. Promptly return the product to Sedgwick; 2670 Executive Drive, Suite A; Indianapolis, IN 46241; Attn: Event 8637 using the enclosed pre-paid UPS label. **All returns are requested to be completed within six months of this notice date.** If you received this notification without the prepaid UPS label and BRF, require additional shipping labels, or have questions regarding the return procedure, please contact Sedgwick at 800-805-3093.

If you have further distributed the recalled product, please notify your accounts and/or additional locations which may have received the recalled product. Please conduct a sub-recall to those accounts and communicate this recall information immediately. Please request they immediately cease distribution and quarantine the affected product. Promptly contact Sedgwick at 800-805-3093 (Mon.-Fri. 8 am-5 pm ET) to obtain pre-paid shipping labels to initiate the return process.

Reimbursement for the returned product will be made by credit memorandum. Please contact Pfizer Customer Service at 844-646-4398 (Mon.-Fri. 8 am-6 pm ET) or your Pfizer representative regarding product availability and questions regarding this market action.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. We appreciate your immediate attention and cooperation and sincerely regret any inconvenience this action may cause you.



If you have any medical questions regarding the product, please call the appropriate contact center below.

Contact Center	Contact Information	Area of Support
Pfizer Medical Information	800-438-1985, option 3 (Mon.-Fri. 9 am-5 pm ET) www.pfizermedinfo.com	For medical questions regarding the product
Pfizer Drug Safety	800-438-1985, option 1 (24 hours a day; 7 days a week)	To report adverse events and product complaints



Sincerely,

Najah Sampson
Commercial Lead, U.S. Hospital
Pfizer

Bicillin® L-A 2 mL Product Labeling



Bicillin® L-A 4 mL Product Labeling



Bicillin® L-A Product Photos

